nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—Vandetanib—VEGFA—muscle cancer	0.0056	1	CrCbGaD
Bosutinib—STK24—Teniposide—Etoposide—muscle cancer	0.00201	0.17	CbGdCrCtD
Bosutinib—CASK—Teniposide—Etoposide—muscle cancer	0.0013	0.109	CbGdCrCtD
Bosutinib—CDK2—Vinblastine—Vincristine—muscle cancer	0.00127	0.107	CbGdCrCtD
Bosutinib—Febrile neutropenia—Doxorubicin—muscle cancer	0.00118	0.00633	CcSEcCtD
Bosutinib—Dehydration—Vincristine—muscle cancer	0.00114	0.00612	CcSEcCtD
Bosutinib—Pancytopenia—Dactinomycin—muscle cancer	0.00112	0.00604	CcSEcCtD
Bosutinib—Neutropenia—Dactinomycin—muscle cancer	0.00111	0.00595	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.0011	0.00592	CcSEcCtD
Bosutinib—WEE1—Daunorubicin—Doxorubicin—muscle cancer	0.00109	0.0919	CbGdCrCtD
Bosutinib—Pleural effusion—Methotrexate—muscle cancer	0.00107	0.00574	CcSEcCtD
Bosutinib—Pneumonia—Dactinomycin—muscle cancer	0.00106	0.00571	CcSEcCtD
Bosutinib—Hepatotoxicity—Methotrexate—muscle cancer	0.00106	0.00569	CcSEcCtD
Bosutinib—Pancytopenia—Vincristine—muscle cancer	0.001	0.0054	CcSEcCtD
Bosutinib—Neutropenia—Vincristine—muscle cancer	0.000989	0.00532	CcSEcCtD
Bosutinib—Agranulocytosis—Dactinomycin—muscle cancer	0.000985	0.00529	CcSEcCtD
Bosutinib—Pneumonia—Vincristine—muscle cancer	0.000948	0.0051	CcSEcCtD
Bosutinib—Hepatitis—Dactinomycin—muscle cancer	0.000947	0.00509	CcSEcCtD
Bosutinib—Pleural effusion—Doxorubicin—muscle cancer	0.000925	0.00497	CcSEcCtD
Bosutinib—Erythema multiforme—Dactinomycin—muscle cancer	0.000896	0.00482	CcSEcCtD
Bosutinib—CHEK2—Vindesine—Vincristine—muscle cancer	0.000894	0.0755	CbGdCrCtD
Bosutinib—Alanine aminotransferase increased—Etoposide—muscle cancer	0.000874	0.0047	CcSEcCtD
Bosutinib—Liver injury—Doxorubicin—muscle cancer	0.000842	0.00452	CcSEcCtD
Bosutinib—Urinary tract disorder—Vincristine—muscle cancer	0.000836	0.00449	CcSEcCtD
Bosutinib—ERBB3—Podofilox—Etoposide—muscle cancer	0.000835	0.0705	CbGdCrCtD
Bosutinib—Respiratory failure—Methotrexate—muscle cancer	0.000833	0.00448	CcSEcCtD
Bosutinib—Connective tissue disorder—Vincristine—muscle cancer	0.000832	0.00447	CcSEcCtD
Bosutinib—Urethral disorder—Vincristine—muscle cancer	0.00083	0.00446	CcSEcCtD
Bosutinib—Pancytopenia—Etoposide—muscle cancer	0.000814	0.00437	CcSEcCtD
Bosutinib—Neutropenia—Etoposide—muscle cancer	0.000801	0.00431	CcSEcCtD
Bosutinib—Cardiac disorder—Vincristine—muscle cancer	0.000786	0.00422	CcSEcCtD
Bosutinib—Pneumonia—Etoposide—muscle cancer	0.000768	0.00413	CcSEcCtD
Bosutinib—Ill-defined disorder—Dactinomycin—muscle cancer	0.000765	0.00411	CcSEcCtD
Bosutinib—Infestation—Etoposide—muscle cancer	0.000764	0.00411	CcSEcCtD
Bosutinib—Infestation NOS—Etoposide—muscle cancer	0.000764	0.00411	CcSEcCtD
Bosutinib—Mediastinal disorder—Vincristine—muscle cancer	0.000763	0.0041	CcSEcCtD
Bosutinib—Anaemia—Dactinomycin—muscle cancer	0.000762	0.0041	CcSEcCtD
Bosutinib—Renal failure—Etoposide—muscle cancer	0.000751	0.00404	CcSEcCtD
Bosutinib—Blood bilirubin increased—Doxorubicin—muscle cancer	0.000749	0.00403	CcSEcCtD
Bosutinib—Malaise—Dactinomycin—muscle cancer	0.000744	0.004	CcSEcCtD
Bosutinib—Leukopenia—Dactinomycin—muscle cancer	0.000738	0.00397	CcSEcCtD
Bosutinib—Hepatobiliary disease—Etoposide—muscle cancer	0.000722	0.00388	CcSEcCtD
Bosutinib—Agranulocytosis—Etoposide—muscle cancer	0.000713	0.00383	CcSEcCtD
Bosutinib—Back pain—Vincristine—muscle cancer	0.000713	0.00383	CcSEcCtD
Bosutinib—MAP3K7—cardiac atrium—muscle cancer	0.00071	0.00194	CbGeAlD
Bosutinib—CSK—tendon—muscle cancer	0.00071	0.00194	CbGeAlD
Bosutinib—MAP4K5—smooth muscle tissue—muscle cancer	0.000709	0.00194	CbGeAlD
Bosutinib—EPHB3—vagina—muscle cancer	0.000708	0.00194	CbGeAlD
Bosutinib—STK36—vagina—muscle cancer	0.000708	0.00194	CbGeAlD
Bosutinib—TNK2—head—muscle cancer	0.000707	0.00193	CbGeAlD
Bosutinib—CSNK1A1—tendon—muscle cancer	0.000705	0.00193	CbGeAlD
Bosutinib—Myalgia—Dactinomycin—muscle cancer	0.000702	0.00377	CcSEcCtD
Bosutinib—TBK1—cardiac atrium—muscle cancer	0.000702	0.00192	CbGeAlD
Bosutinib—HCK—tendon—muscle cancer	0.000701	0.00192	CbGeAlD
Bosutinib—CLK1—tendon—muscle cancer	0.000701	0.00192	CbGeAlD
Bosutinib—MERTK—vagina—muscle cancer	0.0007	0.00191	CbGeAlD
Bosutinib—FYN—renal system—muscle cancer	0.000699	0.00191	CbGeAlD
Bosutinib—ABL2—tendon—muscle cancer	0.000697	0.00191	CbGeAlD
Bosutinib—MAP3K19—testis—muscle cancer	0.000696	0.0019	CbGeAlD
Bosutinib—MAP4K1—testis—muscle cancer	0.000696	0.0019	CbGeAlD
Bosutinib—Hyperkalaemia—Doxorubicin—muscle cancer	0.000696	0.00374	CcSEcCtD
Bosutinib—Discomfort—Dactinomycin—muscle cancer	0.000694	0.00373	CcSEcCtD
Bosutinib—BTK—testis—muscle cancer	0.000693	0.00189	CbGeAlD
Bosutinib—MAP2K1—bone marrow—muscle cancer	0.000692	0.00189	CbGeAlD
Bosutinib—BMP2K—tendon—muscle cancer	0.000688	0.00188	CbGeAlD
Bosutinib—CAMK2G—tendon—muscle cancer	0.000688	0.00188	CbGeAlD
Bosutinib—CSK—bone marrow—muscle cancer	0.000688	0.00188	CbGeAlD
Bosutinib—ERBB4—head—muscle cancer	0.000687	0.00188	CbGeAlD
Bosutinib—STK3—head—muscle cancer	0.000687	0.00188	CbGeAlD
Bosutinib—MAP4K4—vagina—muscle cancer	0.000687	0.00188	CbGeAlD
Bosutinib—CSNK1A1—bone marrow—muscle cancer	0.000683	0.00187	CbGeAlD
Bosutinib—TNK2—testis—muscle cancer	0.000683	0.00187	CbGeAlD
Bosutinib—LRRK2—tendon—muscle cancer	0.000682	0.00187	CbGeAlD
Bosutinib—NUAK2—vagina—muscle cancer	0.000682	0.00186	CbGeAlD
Bosutinib—BCR—vagina—muscle cancer	0.000682	0.00186	CbGeAlD
Bosutinib—Anaemia—Vincristine—muscle cancer	0.000681	0.00366	CcSEcCtD
Bosutinib—CLK1—bone marrow—muscle cancer	0.000679	0.00186	CbGeAlD
Bosutinib—HCK—bone marrow—muscle cancer	0.000679	0.00186	CbGeAlD
Bosutinib—ROCK1—head—muscle cancer	0.000678	0.00186	CbGeAlD
Bosutinib—Urinary tract disorder—Etoposide—muscle cancer	0.000677	0.00364	CcSEcCtD
Bosutinib—MAP3K12—vagina—muscle cancer	0.000677	0.00185	CbGeAlD
Bosutinib—RPS6KB1—cardiac atrium—muscle cancer	0.000675	0.00185	CbGeAlD
Bosutinib—Oedema—Dactinomycin—muscle cancer	0.000673	0.00362	CcSEcCtD
Bosutinib—MAP4K2—testis—muscle cancer	0.000673	0.00184	CbGeAlD
Bosutinib—Fluid retention—Doxorubicin—muscle cancer	0.000672	0.00361	CcSEcCtD
Bosutinib—Urethral disorder—Etoposide—muscle cancer	0.000672	0.00361	CcSEcCtD
Bosutinib—Infection—Dactinomycin—muscle cancer	0.000669	0.00359	CcSEcCtD
Bosutinib—AXL—cardiac atrium—muscle cancer	0.000668	0.00183	CbGeAlD
Bosutinib—BMP2K—bone marrow—muscle cancer	0.000666	0.00182	CbGeAlD
Bosutinib—CAMK2G—bone marrow—muscle cancer	0.000666	0.00182	CbGeAlD
Bosutinib—PTK2B—tendon—muscle cancer	0.000664	0.00182	CbGeAlD
Bosutinib—ERBB4—testis—muscle cancer	0.000664	0.00182	CbGeAlD
Bosutinib—STK3—testis—muscle cancer	0.000664	0.00182	CbGeAlD
Bosutinib—STK35—vagina—muscle cancer	0.000663	0.00181	CbGeAlD
Bosutinib—LRRK2—bone marrow—muscle cancer	0.00066	0.00181	CbGeAlD
Bosutinib—Leukopenia—Vincristine—muscle cancer	0.00066	0.00355	CcSEcCtD
Bosutinib—Thrombocytopenia—Dactinomycin—muscle cancer	0.000659	0.00354	CcSEcCtD
Bosutinib—BMPR2—head—muscle cancer	0.000659	0.0018	CbGeAlD
Bosutinib—CSK—vagina—muscle cancer	0.000659	0.0018	CbGeAlD
Bosutinib—ROCK1—testis—muscle cancer	0.000655	0.00179	CbGeAlD
Bosutinib—YES1—smooth muscle tissue—muscle cancer	0.000655	0.00179	CbGeAlD
Bosutinib—CSNK1A1—vagina—muscle cancer	0.000655	0.00179	CbGeAlD
Bosutinib—STK36—head—muscle cancer	0.000654	0.00179	CbGeAlD
Bosutinib—EPHB3—head—muscle cancer	0.000654	0.00179	CbGeAlD
Bosutinib—CSNK1E—tendon—muscle cancer	0.000654	0.00179	CbGeAlD
Bosutinib—HCK—vagina—muscle cancer	0.00065	0.00178	CbGeAlD
Bosutinib—CLK1—vagina—muscle cancer	0.00065	0.00178	CbGeAlD
Bosutinib—Erythema multiforme—Etoposide—muscle cancer	0.000648	0.00349	CcSEcCtD
Bosutinib—ABL2—vagina—muscle cancer	0.000646	0.00177	CbGeAlD
Bosutinib—MERTK—head—muscle cancer	0.000646	0.00177	CbGeAlD
Bosutinib—Rash maculo-papular—Doxorubicin—muscle cancer	0.000644	0.00346	CcSEcCtD
Bosutinib—PTK2B—bone marrow—muscle cancer	0.000644	0.00176	CbGeAlD
Bosutinib—SIK1—tendon—muscle cancer	0.000644	0.00176	CbGeAlD
Bosutinib—IRAK4—tendon—muscle cancer	0.000644	0.00176	CbGeAlD
Bosutinib—SLK—cardiac atrium—muscle cancer	0.000643	0.00176	CbGeAlD
Bosutinib—Renal failure acute—Methotrexate—muscle cancer	0.000643	0.00346	CcSEcCtD
Bosutinib—EPHB4—cardiac atrium—muscle cancer	0.000639	0.00175	CbGeAlD
Bosutinib—CAMK2G—vagina—muscle cancer	0.000638	0.00175	CbGeAlD
Bosutinib—BMP2K—vagina—muscle cancer	0.000638	0.00175	CbGeAlD
Bosutinib—PDGFRB—embryo—muscle cancer	0.000638	0.00175	CbGeAlD
Bosutinib—EPHA4—tendon—muscle cancer	0.000637	0.00174	CbGeAlD
Bosutinib—BMPR2—testis—muscle cancer	0.000637	0.00174	CbGeAlD
Bosutinib—Cardiac disorder—Etoposide—muscle cancer	0.000636	0.00342	CcSEcCtD
Bosutinib—MAP4K4—head—muscle cancer	0.000634	0.00174	CbGeAlD
Bosutinib—LRRK2—vagina—muscle cancer	0.000633	0.00173	CbGeAlD
Bosutinib—STK36—testis—muscle cancer	0.000632	0.00173	CbGeAlD
Bosutinib—EPHB3—testis—muscle cancer	0.000632	0.00173	CbGeAlD
Bosutinib—YES1—renal system—muscle cancer	0.00063	0.00172	CbGeAlD
Bosutinib—SRC—smooth muscle tissue—muscle cancer	0.00063	0.00172	CbGeAlD
Bosutinib—BCR—head—muscle cancer	0.00063	0.00172	CbGeAlD
Bosutinib—ULK3—tendon—muscle cancer	0.000629	0.00172	CbGeAlD
Bosutinib—MAP2K2—tendon—muscle cancer	0.000629	0.00172	CbGeAlD
Bosutinib—Myalgia—Vincristine—muscle cancer	0.000627	0.00337	CcSEcCtD
Bosutinib—EPHA2—cardiac atrium—muscle cancer	0.000627	0.00171	CbGeAlD
Bosutinib—FYN—cardiac atrium—muscle cancer	0.000626	0.00171	CbGeAlD
Bosutinib—MAP3K12—head—muscle cancer	0.000625	0.00171	CbGeAlD
Bosutinib—STK10—renal system—muscle cancer	0.000625	0.00171	CbGeAlD
Bosutinib—MERTK—testis—muscle cancer	0.000624	0.00171	CbGeAlD
Bosutinib—SIK1—bone marrow—muscle cancer	0.000623	0.00171	CbGeAlD
Bosutinib—IRAK4—bone marrow—muscle cancer	0.000623	0.00171	CbGeAlD
Bosutinib—TAOK3—renal system—muscle cancer	0.000622	0.0017	CbGeAlD
Bosutinib—Immune system disorder—Etoposide—muscle cancer	0.000619	0.00333	CcSEcCtD
Bosutinib—MAP3K7—tendon—muscle cancer	0.000619	0.00169	CbGeAlD
Bosutinib—Mediastinal disorder—Etoposide—muscle cancer	0.000618	0.00332	CcSEcCtD
Bosutinib—PTK2B—vagina—muscle cancer	0.000617	0.00169	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000613	0.0033	CcSEcCtD
Bosutinib—MAP4K4—testis—muscle cancer	0.000613	0.00168	CbGeAlD
Bosutinib—STK35—head—muscle cancer	0.000613	0.00168	CbGeAlD
Bosutinib—MAP2K1—head—muscle cancer	0.000613	0.00168	CbGeAlD
Bosutinib—TBK1—tendon—muscle cancer	0.000612	0.00167	CbGeAlD
Bosutinib—PTK2—tendon—muscle cancer	0.000612	0.00167	CbGeAlD
Bosutinib—MAP4K5—cardiac atrium—muscle cancer	0.000611	0.00167	CbGeAlD
Bosutinib—MAP3K3—cardiac atrium—muscle cancer	0.000611	0.00167	CbGeAlD
Bosutinib—MAP2K2—bone marrow—muscle cancer	0.00061	0.00167	CbGeAlD
Bosutinib—ULK3—bone marrow—muscle cancer	0.00061	0.00167	CbGeAlD
Bosutinib—CSK—head—muscle cancer	0.000609	0.00166	CbGeAlD
Bosutinib—NUAK2—testis—muscle cancer	0.000608	0.00166	CbGeAlD
Bosutinib—BCR—testis—muscle cancer	0.000608	0.00166	CbGeAlD
Bosutinib—CSNK1E—vagina—muscle cancer	0.000607	0.00166	CbGeAlD
Bosutinib—SRC—renal system—muscle cancer	0.000607	0.00166	CbGeAlD
Bosutinib—MAP3K2—bone marrow—muscle cancer	0.000605	0.00166	CbGeAlD
Bosutinib—CSNK1A1—head—muscle cancer	0.000605	0.00165	CbGeAlD
Bosutinib—MAP3K12—testis—muscle cancer	0.000604	0.00165	CbGeAlD
Bosutinib—Anaphylactic shock—Vincristine—muscle cancer	0.000601	0.00323	CcSEcCtD
Bosutinib—Oedema—Vincristine—muscle cancer	0.000601	0.00323	CcSEcCtD
Bosutinib—CLK1—head—muscle cancer	0.000601	0.00164	CbGeAlD
Bosutinib—HCK—head—muscle cancer	0.000601	0.00164	CbGeAlD
Bosutinib—IRAK1—tendon—muscle cancer	0.0006	0.00164	CbGeAlD
Bosutinib—MAP3K7—bone marrow—muscle cancer	0.000599	0.00164	CbGeAlD
Bosutinib—Infection—Vincristine—muscle cancer	0.000597	0.00321	CcSEcCtD
Bosutinib—IRAK4—vagina—muscle cancer	0.000597	0.00163	CbGeAlD
Bosutinib—TBK1—bone marrow—muscle cancer	0.000593	0.00162	CbGeAlD
Bosutinib—MAP2K1—testis—muscle cancer	0.000592	0.00162	CbGeAlD
Bosutinib—STK35—testis—muscle cancer	0.000592	0.00162	CbGeAlD
Bosutinib—EPHA4—vagina—muscle cancer	0.000591	0.00162	CbGeAlD
Bosutinib—Nervous system disorder—Vincristine—muscle cancer	0.00059	0.00317	CcSEcCtD
Bosutinib—BMP2K—head—muscle cancer	0.00059	0.00161	CbGeAlD
Bosutinib—CAMK2G—head—muscle cancer	0.00059	0.00161	CbGeAlD
Bosutinib—Thrombocytopenia—Vincristine—muscle cancer	0.000589	0.00317	CcSEcCtD
Bosutinib—RPS6KB1—tendon—muscle cancer	0.000589	0.00161	CbGeAlD
Bosutinib—Hepatic function abnormal—Doxorubicin—muscle cancer	0.000588	0.00316	CcSEcCtD
Bosutinib—CSK—testis—muscle cancer	0.000588	0.00161	CbGeAlD
Bosutinib—Decreased appetite—Dactinomycin—muscle cancer	0.000585	0.00315	CcSEcCtD
Bosutinib—FGR—tendon—muscle cancer	0.000585	0.0016	CbGeAlD
Bosutinib—Dysgeusia—Etoposide—muscle cancer	0.000585	0.00314	CcSEcCtD
Bosutinib—LRRK2—head—muscle cancer	0.000584	0.0016	CbGeAlD
Bosutinib—CSNK1A1—testis—muscle cancer	0.000584	0.0016	CbGeAlD
Bosutinib—ULK3—vagina—muscle cancer	0.000584	0.0016	CbGeAlD
Bosutinib—AXL—tendon—muscle cancer	0.000583	0.00159	CbGeAlD
Bosutinib—IRAK1—bone marrow—muscle cancer	0.000581	0.00159	CbGeAlD
Bosutinib—HCK—testis—muscle cancer	0.00058	0.00159	CbGeAlD
Bosutinib—CLK1—testis—muscle cancer	0.00058	0.00159	CbGeAlD
Bosutinib—Fatigue—Dactinomycin—muscle cancer	0.00058	0.00312	CcSEcCtD
Bosutinib—Back pain—Etoposide—muscle cancer	0.000577	0.0031	CcSEcCtD
Bosutinib—ABL2—testis—muscle cancer	0.000577	0.00158	CbGeAlD
Bosutinib—Pain—Dactinomycin—muscle cancer	0.000576	0.00309	CcSEcCtD
Bosutinib—ERBB3—Vinblastine—Vincristine—muscle cancer	0.000575	0.0485	CbGdCrCtD
Bosutinib—MAP3K7—vagina—muscle cancer	0.000574	0.00157	CbGeAlD
Bosutinib—RPS6KB1—bone marrow—muscle cancer	0.00057	0.00156	CbGeAlD
Bosutinib—BMP2K—testis—muscle cancer	0.00057	0.00156	CbGeAlD
Bosutinib—CAMK2G—testis—muscle cancer	0.00057	0.00156	CbGeAlD
Bosutinib—PTK2B—head—muscle cancer	0.00057	0.00156	CbGeAlD
Bosutinib—ABL1—embryo—muscle cancer	0.000569	0.00156	CbGeAlD
Bosutinib—TBK1—vagina—muscle cancer	0.000568	0.00155	CbGeAlD
Bosutinib—PTK2—vagina—muscle cancer	0.000568	0.00155	CbGeAlD
Bosutinib—LCK—bone marrow—muscle cancer	0.000567	0.00155	CbGeAlD
Bosutinib—FGR—bone marrow—muscle cancer	0.000567	0.00155	CbGeAlD
Bosutinib—CSF1R—smooth muscle tissue—muscle cancer	0.000566	0.00155	CbGeAlD
Bosutinib—YES1—cardiac atrium—muscle cancer	0.000565	0.00154	CbGeAlD
Bosutinib—LRRK2—testis—muscle cancer	0.000565	0.00154	CbGeAlD
Bosutinib—CHEK2—Vinorelbine—Vincristine—muscle cancer	0.000564	0.0477	CbGdCrCtD
Bosutinib—CHEK2—Teniposide—Etoposide—muscle cancer	0.000564	0.0476	CbGdCrCtD
Bosutinib—CHEK2—Podofilox—Etoposide—muscle cancer	0.000564	0.0476	CbGdCrCtD
Bosutinib—EGFR—testis—muscle cancer	0.000563	0.00154	CbGeAlD
Bosutinib—SLK—tendon—muscle cancer	0.000561	0.00153	CbGeAlD
Bosutinib—CSNK1E—head—muscle cancer	0.00056	0.00153	CbGeAlD
Bosutinib—TAOK3—cardiac atrium—muscle cancer	0.000557	0.00152	CbGeAlD
Bosutinib—Renal failure acute—Doxorubicin—muscle cancer	0.000557	0.00299	CcSEcCtD
Bosutinib—EPHB4—tendon—muscle cancer	0.000557	0.00152	CbGeAlD
Bosutinib—Feeling abnormal—Dactinomycin—muscle cancer	0.000555	0.00298	CcSEcCtD
Bosutinib—Ill-defined disorder—Etoposide—muscle cancer	0.000554	0.00298	CcSEcCtD
Bosutinib—Anaemia—Etoposide—muscle cancer	0.000552	0.00297	CcSEcCtD
Bosutinib—SIK1—head—muscle cancer	0.000552	0.00151	CbGeAlD
Bosutinib—IRAK4—head—muscle cancer	0.000552	0.00151	CbGeAlD
Bosutinib—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00055	0.00296	CcSEcCtD
Bosutinib—PTK2B—testis—muscle cancer	0.00055	0.00151	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000548	0.00295	CcSEcCtD
Bosutinib—EPHA2—tendon—muscle cancer	0.000546	0.00149	CbGeAlD
Bosutinib—RPS6KB1—vagina—muscle cancer	0.000546	0.00149	CbGeAlD
Bosutinib—EPHA4—head—muscle cancer	0.000546	0.00149	CbGeAlD
Bosutinib—FYN—tendon—muscle cancer	0.000545	0.00149	CbGeAlD
Bosutinib—SLK—bone marrow—muscle cancer	0.000543	0.00149	CbGeAlD
Bosutinib—SRC—cardiac atrium—muscle cancer	0.000543	0.00149	CbGeAlD
Bosutinib—LCK—vagina—muscle cancer	0.000543	0.00148	CbGeAlD
Bosutinib—FGR—vagina—muscle cancer	0.000543	0.00148	CbGeAlD
Bosutinib—CSNK1E—testis—muscle cancer	0.000541	0.00148	CbGeAlD
Bosutinib—ERBB3—head—muscle cancer	0.000541	0.00148	CbGeAlD
Bosutinib—AXL—vagina—muscle cancer	0.000541	0.00148	CbGeAlD
Bosutinib—Renal impairment—Doxorubicin—muscle cancer	0.00054	0.0029	CcSEcCtD
Bosutinib—ULK3—head—muscle cancer	0.000539	0.00148	CbGeAlD
Bosutinib—MAP2K2—head—muscle cancer	0.000539	0.00148	CbGeAlD
Bosutinib—EPHB4—bone marrow—muscle cancer	0.000539	0.00148	CbGeAlD
Bosutinib—Malaise—Etoposide—muscle cancer	0.000538	0.00289	CcSEcCtD
Bosutinib—MAP3K2—head—muscle cancer	0.000535	0.00146	CbGeAlD
Bosutinib—Leukopenia—Etoposide—muscle cancer	0.000534	0.00287	CcSEcCtD
Bosutinib—MAP4K5—tendon—muscle cancer	0.000533	0.00146	CbGeAlD
Bosutinib—MAP3K3—tendon—muscle cancer	0.000533	0.00146	CbGeAlD
Bosutinib—SIK1—testis—muscle cancer	0.000533	0.00146	CbGeAlD
Bosutinib—IRAK4—testis—muscle cancer	0.000533	0.00146	CbGeAlD
Bosutinib—Abdominal pain—Dactinomycin—muscle cancer	0.000532	0.00286	CcSEcCtD
Bosutinib—Body temperature increased—Dactinomycin—muscle cancer	0.000532	0.00286	CcSEcCtD
Bosutinib—FYN—bone marrow—muscle cancer	0.000528	0.00144	CbGeAlD
Bosutinib—EPHA4—testis—muscle cancer	0.000527	0.00144	CbGeAlD
Bosutinib—TBK1—head—muscle cancer	0.000524	0.00143	CbGeAlD
Bosutinib—PTK2—head—muscle cancer	0.000524	0.00143	CbGeAlD
Bosutinib—Decreased appetite—Vincristine—muscle cancer	0.000523	0.00281	CcSEcCtD
Bosutinib—ERBB3—testis—muscle cancer	0.000522	0.00143	CbGeAlD
Bosutinib—MAP2K2—testis—muscle cancer	0.000521	0.00143	CbGeAlD
Bosutinib—ULK3—testis—muscle cancer	0.000521	0.00143	CbGeAlD
Bosutinib—Cough—Etoposide—muscle cancer	0.000521	0.0028	CcSEcCtD
Bosutinib—SLK—vagina—muscle cancer	0.00052	0.00142	CbGeAlD
Bosutinib—Gastrointestinal disorder—Vincristine—muscle cancer	0.000519	0.00279	CcSEcCtD
Bosutinib—Fatigue—Vincristine—muscle cancer	0.000518	0.00279	CcSEcCtD
Bosutinib—MAP3K2—testis—muscle cancer	0.000517	0.00142	CbGeAlD
Bosutinib—EPHB4—vagina—muscle cancer	0.000517	0.00141	CbGeAlD
Bosutinib—MAP4K5—bone marrow—muscle cancer	0.000516	0.00141	CbGeAlD
Bosutinib—MAP3K3—bone marrow—muscle cancer	0.000516	0.00141	CbGeAlD
Bosutinib—Pain—Vincristine—muscle cancer	0.000514	0.00276	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.000514	0.00276	CcSEcCtD
Bosutinib—MAP3K7—testis—muscle cancer	0.000512	0.0014	CbGeAlD
Bosutinib—Chest pain—Etoposide—muscle cancer	0.000508	0.00273	CcSEcCtD
Bosutinib—EPHA2—vagina—muscle cancer	0.000507	0.00139	CbGeAlD
Bosutinib—TBK1—testis—muscle cancer	0.000507	0.00139	CbGeAlD
Bosutinib—PTK2—testis—muscle cancer	0.000507	0.00139	CbGeAlD
Bosutinib—FYN—vagina—muscle cancer	0.000506	0.00138	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000505	0.00271	CcSEcCtD
Bosutinib—RPS6KB1—head—muscle cancer	0.000504	0.00138	CbGeAlD
Bosutinib—Discomfort—Etoposide—muscle cancer	0.000502	0.0027	CcSEcCtD
Bosutinib—PDGFRB—smooth muscle tissue—muscle cancer	0.000502	0.00137	CbGeAlD
Bosutinib—FGR—head—muscle cancer	0.000501	0.00137	CbGeAlD
Bosutinib—MAP2K5—cardiac atrium—muscle cancer	0.0005	0.00137	CbGeAlD
Bosutinib—AXL—head—muscle cancer	0.000499	0.00137	CbGeAlD
Bosutinib—IRAK1—testis—muscle cancer	0.000497	0.00136	CbGeAlD
Bosutinib—Face oedema—Doxorubicin—muscle cancer	0.000496	0.00267	CcSEcCtD
Bosutinib—MAP4K5—vagina—muscle cancer	0.000494	0.00135	CbGeAlD
Bosutinib—MAP3K3—vagina—muscle cancer	0.000494	0.00135	CbGeAlD
Bosutinib—YES1—tendon—muscle cancer	0.000492	0.00135	CbGeAlD
Bosutinib—Abdominal discomfort—Methotrexate—muscle cancer	0.000492	0.00264	CcSEcCtD
Bosutinib—Gastrointestinal pain—Vincristine—muscle cancer	0.000492	0.00264	CcSEcCtD
Bosutinib—STK10—tendon—muscle cancer	0.000488	0.00133	CbGeAlD
Bosutinib—CSF1R—cardiac atrium—muscle cancer	0.000488	0.00133	CbGeAlD
Bosutinib—RPS6KB1—testis—muscle cancer	0.000487	0.00133	CbGeAlD
Bosutinib—Pancytopenia—Methotrexate—muscle cancer	0.000487	0.00262	CcSEcCtD
Bosutinib—Anaphylactic shock—Etoposide—muscle cancer	0.000487	0.00262	CcSEcCtD
Bosutinib—TAOK3—tendon—muscle cancer	0.000486	0.00133	CbGeAlD
Bosutinib—FGR—testis—muscle cancer	0.000484	0.00133	CbGeAlD
Bosutinib—LCK—testis—muscle cancer	0.000484	0.00133	CbGeAlD
Bosutinib—Infection—Etoposide—muscle cancer	0.000484	0.0026	CcSEcCtD
Bosutinib—Asthenia—Dactinomycin—muscle cancer	0.000483	0.0026	CcSEcCtD
Bosutinib—PDGFRB—renal system—muscle cancer	0.000483	0.00132	CbGeAlD
Bosutinib—AXL—testis—muscle cancer	0.000482	0.00132	CbGeAlD
Bosutinib—Blood creatinine increased—Doxorubicin—muscle cancer	0.000482	0.00259	CcSEcCtD
Bosutinib—Neutropenia—Methotrexate—muscle cancer	0.00048	0.00258	CcSEcCtD
Bosutinib—Dehydration—Doxorubicin—muscle cancer	0.000478	0.00257	CcSEcCtD
Bosutinib—Thrombocytopenia—Etoposide—muscle cancer	0.000477	0.00256	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000477	0.00256	CcSEcCtD
Bosutinib—YES1—bone marrow—muscle cancer	0.000477	0.0013	CbGeAlD
Bosutinib—Abdominal pain—Vincristine—muscle cancer	0.000475	0.00256	CcSEcCtD
Bosutinib—Body temperature increased—Vincristine—muscle cancer	0.000475	0.00256	CcSEcCtD
Bosutinib—Skin disorder—Etoposide—muscle cancer	0.000473	0.00254	CcSEcCtD
Bosutinib—STK10—bone marrow—muscle cancer	0.000472	0.00129	CbGeAlD
Bosutinib—TAOK3—bone marrow—muscle cancer	0.000471	0.00129	CbGeAlD
Bosutinib—Abdominal pain upper—Doxorubicin—muscle cancer	0.00047	0.00252	CcSEcCtD
Bosutinib—EPHA2—head—muscle cancer	0.000468	0.00128	CbGeAlD
Bosutinib—FYN—head—muscle cancer	0.000467	0.00128	CbGeAlD
Bosutinib—SLK—testis—muscle cancer	0.000464	0.00127	CbGeAlD
Bosutinib—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000463	0.00249	CcSEcCtD
Bosutinib—EPHB4—testis—muscle cancer	0.000461	0.00126	CbGeAlD
Bosutinib—Diarrhoea—Dactinomycin—muscle cancer	0.000461	0.00248	CcSEcCtD
Bosutinib—Pneumonia—Methotrexate—muscle cancer	0.00046	0.00247	CcSEcCtD
Bosutinib—Nasopharyngitis—Doxorubicin—muscle cancer	0.00046	0.00247	CcSEcCtD
Bosutinib—Infestation—Methotrexate—muscle cancer	0.000458	0.00246	CcSEcCtD
Bosutinib—Infestation NOS—Methotrexate—muscle cancer	0.000458	0.00246	CcSEcCtD
Bosutinib—MAP3K3—head—muscle cancer	0.000457	0.00125	CbGeAlD
Bosutinib—MAP4K5—head—muscle cancer	0.000457	0.00125	CbGeAlD
Bosutinib—YES1—vagina—muscle cancer	0.000457	0.00125	CbGeAlD
Bosutinib—Gastritis—Doxorubicin—muscle cancer	0.000455	0.00245	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000453	0.00244	CcSEcCtD
Bosutinib—STK10—vagina—muscle cancer	0.000453	0.00124	CbGeAlD
Bosutinib—EPHA2—testis—muscle cancer	0.000452	0.00124	CbGeAlD
Bosutinib—FYN—testis—muscle cancer	0.000452	0.00124	CbGeAlD
Bosutinib—TAOK3—vagina—muscle cancer	0.000451	0.00123	CbGeAlD
Bosutinib—Renal failure—Methotrexate—muscle cancer	0.00045	0.00242	CcSEcCtD
Bosutinib—ABL1—smooth muscle tissue—muscle cancer	0.000447	0.00122	CbGeAlD
Bosutinib—Influenza—Doxorubicin—muscle cancer	0.000444	0.00239	CcSEcCtD
Bosutinib—MAP3K3—testis—muscle cancer	0.000441	0.00121	CbGeAlD
Bosutinib—MAP4K5—testis—muscle cancer	0.000441	0.00121	CbGeAlD
Bosutinib—MAP2K5—tendon—muscle cancer	0.000436	0.00119	CbGeAlD
Bosutinib—Dyspnoea—Etoposide—muscle cancer	0.000434	0.00233	CcSEcCtD
Bosutinib—Hepatobiliary disease—Methotrexate—muscle cancer	0.000433	0.00233	CcSEcCtD
Bosutinib—PDGFRB—cardiac atrium—muscle cancer	0.000432	0.00118	CbGeAlD
Bosutinib—Asthenia—Vincristine—muscle cancer	0.000431	0.00232	CcSEcCtD
Bosutinib—ABL1—renal system—muscle cancer	0.00043	0.00118	CbGeAlD
Bosutinib—Vomiting—Dactinomycin—muscle cancer	0.000428	0.0023	CcSEcCtD
Bosutinib—Bronchitis—Doxorubicin—muscle cancer	0.000427	0.0023	CcSEcCtD
Bosutinib—Agranulocytosis—Methotrexate—muscle cancer	0.000427	0.0023	CcSEcCtD
Bosutinib—CSF1R—tendon—muscle cancer	0.000425	0.00116	CbGeAlD
Bosutinib—Rash—Dactinomycin—muscle cancer	0.000424	0.00228	CcSEcCtD
Bosutinib—Decreased appetite—Etoposide—muscle cancer	0.000423	0.00228	CcSEcCtD
Bosutinib—Pancytopenia—Doxorubicin—muscle cancer	0.000422	0.00227	CcSEcCtD
Bosutinib—YES1—head—muscle cancer	0.000422	0.00115	CbGeAlD
Bosutinib—Gastrointestinal disorder—Etoposide—muscle cancer	0.000421	0.00226	CcSEcCtD
Bosutinib—Fatigue—Etoposide—muscle cancer	0.00042	0.00226	CcSEcCtD
Bosutinib—STK10—head—muscle cancer	0.000418	0.00114	CbGeAlD
Bosutinib—Pain—Etoposide—muscle cancer	0.000417	0.00224	CcSEcCtD
Bosutinib—TAOK3—head—muscle cancer	0.000416	0.00114	CbGeAlD
Bosutinib—Neutropenia—Doxorubicin—muscle cancer	0.000415	0.00223	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000413	0.00222	CcSEcCtD
Bosutinib—CSF1R—bone marrow—muscle cancer	0.000412	0.00113	CbGeAlD
Bosutinib—Diarrhoea—Vincristine—muscle cancer	0.000411	0.00221	CcSEcCtD
Bosutinib—Hepatitis—Methotrexate—muscle cancer	0.000411	0.00221	CcSEcCtD
Bosutinib—YES1—testis—muscle cancer	0.000408	0.00111	CbGeAlD
Bosutinib—SRC—head—muscle cancer	0.000406	0.00111	CbGeAlD
Bosutinib—Urinary tract disorder—Methotrexate—muscle cancer	0.000406	0.00218	CcSEcCtD
Bosutinib—MAP2K5—vagina—muscle cancer	0.000404	0.00111	CbGeAlD
Bosutinib—STK10—testis—muscle cancer	0.000404	0.0011	CbGeAlD
Bosutinib—Urethral disorder—Methotrexate—muscle cancer	0.000403	0.00216	CcSEcCtD
Bosutinib—TAOK3—testis—muscle cancer	0.000402	0.0011	CbGeAlD
Bosutinib—Feeling abnormal—Etoposide—muscle cancer	0.000401	0.00216	CcSEcCtD
Bosutinib—Nausea—Dactinomycin—muscle cancer	0.0004	0.00215	CcSEcCtD
Bosutinib—Pneumonia—Doxorubicin—muscle cancer	0.000398	0.00214	CcSEcCtD
Bosutinib—Gastrointestinal pain—Etoposide—muscle cancer	0.000398	0.00214	CcSEcCtD
Bosutinib—Dizziness—Vincristine—muscle cancer	0.000398	0.00214	CcSEcCtD
Bosutinib—Infestation NOS—Doxorubicin—muscle cancer	0.000396	0.00213	CcSEcCtD
Bosutinib—Infestation—Doxorubicin—muscle cancer	0.000396	0.00213	CcSEcCtD
Bosutinib—CSF1R—vagina—muscle cancer	0.000394	0.00108	CbGeAlD
Bosutinib—SRC—testis—muscle cancer	0.000392	0.00107	CbGeAlD
Bosutinib—Renal failure—Doxorubicin—muscle cancer	0.000389	0.00209	CcSEcCtD
Bosutinib—Erythema multiforme—Methotrexate—muscle cancer	0.000388	0.00209	CcSEcCtD
Bosutinib—CHEK2—Vinblastine—Vincristine—muscle cancer	0.000388	0.0328	CbGdCrCtD
Bosutinib—Urticaria—Etoposide—muscle cancer	0.000387	0.00208	CcSEcCtD
Bosutinib—ABL1—cardiac atrium—muscle cancer	0.000385	0.00105	CbGeAlD
Bosutinib—Abdominal pain—Etoposide—muscle cancer	0.000385	0.00207	CcSEcCtD
Bosutinib—Body temperature increased—Etoposide—muscle cancer	0.000385	0.00207	CcSEcCtD
Bosutinib—Tinnitus—Methotrexate—muscle cancer	0.000383	0.00206	CcSEcCtD
Bosutinib—Vomiting—Vincristine—muscle cancer	0.000382	0.00206	CcSEcCtD
Bosutinib—Cardiac disorder—Methotrexate—muscle cancer	0.000381	0.00205	CcSEcCtD
Bosutinib—Rash—Vincristine—muscle cancer	0.000379	0.00204	CcSEcCtD
Bosutinib—Dermatitis—Vincristine—muscle cancer	0.000379	0.00204	CcSEcCtD
Bosutinib—PDGFRB—tendon—muscle cancer	0.000377	0.00103	CbGeAlD
Bosutinib—Headache—Vincristine—muscle cancer	0.000377	0.00203	CcSEcCtD
Bosutinib—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000375	0.00201	CcSEcCtD
Bosutinib—MAP2K5—head—muscle cancer	0.000373	0.00102	CbGeAlD
Bosutinib—CSK—Daunorubicin—Doxorubicin—muscle cancer	0.000372	0.0314	CbGdCrCtD
Bosutinib—CSK—Epirubicin—Doxorubicin—muscle cancer	0.000372	0.0314	CbGdCrCtD
Bosutinib—Immune system disorder—Methotrexate—muscle cancer	0.000371	0.00199	CcSEcCtD
Bosutinib—Mediastinal disorder—Methotrexate—muscle cancer	0.00037	0.00199	CcSEcCtD
Bosutinib—Agranulocytosis—Doxorubicin—muscle cancer	0.00037	0.00199	CcSEcCtD
Bosutinib—PDGFRB—bone marrow—muscle cancer	0.000365	0.000999	CbGeAlD
Bosutinib—CSF1R—head—muscle cancer	0.000364	0.000997	CbGeAlD
Bosutinib—MAP2K5—testis—muscle cancer	0.000361	0.000986	CbGeAlD
Bosutinib—Malnutrition—Methotrexate—muscle cancer	0.000358	0.00192	CcSEcCtD
Bosutinib—Nausea—Vincristine—muscle cancer	0.000357	0.00192	CcSEcCtD
Bosutinib—Hepatitis—Doxorubicin—muscle cancer	0.000356	0.00191	CcSEcCtD
Bosutinib—CSF1R—testis—muscle cancer	0.000352	0.000963	CbGeAlD
Bosutinib—Urinary tract disorder—Doxorubicin—muscle cancer	0.000351	0.00189	CcSEcCtD
Bosutinib—Oedema peripheral—Doxorubicin—muscle cancer	0.00035	0.00188	CcSEcCtD
Bosutinib—Dysgeusia—Methotrexate—muscle cancer	0.00035	0.00188	CcSEcCtD
Bosutinib—PDGFRB—vagina—muscle cancer	0.00035	0.000957	CbGeAlD
Bosutinib—Asthenia—Etoposide—muscle cancer	0.00035	0.00188	CcSEcCtD
Bosutinib—Connective tissue disorder—Doxorubicin—muscle cancer	0.000349	0.00188	CcSEcCtD
Bosutinib—Urethral disorder—Doxorubicin—muscle cancer	0.000349	0.00187	CcSEcCtD
Bosutinib—Back pain—Methotrexate—muscle cancer	0.000346	0.00186	CcSEcCtD
Bosutinib—Pruritus—Etoposide—muscle cancer	0.000345	0.00185	CcSEcCtD
Bosutinib—Erythema multiforme—Doxorubicin—muscle cancer	0.000336	0.00181	CcSEcCtD
Bosutinib—ABL1—tendon—muscle cancer	0.000336	0.000919	CbGeAlD
Bosutinib—Diarrhoea—Etoposide—muscle cancer	0.000333	0.00179	CcSEcCtD
Bosutinib—Ill-defined disorder—Methotrexate—muscle cancer	0.000332	0.00178	CcSEcCtD
Bosutinib—Tinnitus—Doxorubicin—muscle cancer	0.000332	0.00178	CcSEcCtD
Bosutinib—Anaemia—Methotrexate—muscle cancer	0.00033	0.00178	CcSEcCtD
Bosutinib—Cardiac disorder—Doxorubicin—muscle cancer	0.00033	0.00177	CcSEcCtD
Bosutinib—ABL1—bone marrow—muscle cancer	0.000325	0.00089	CbGeAlD
Bosutinib—PDGFRB—head—muscle cancer	0.000323	0.000884	CbGeAlD
Bosutinib—Malaise—Methotrexate—muscle cancer	0.000322	0.00173	CcSEcCtD
Bosutinib—Dizziness—Etoposide—muscle cancer	0.000322	0.00173	CcSEcCtD
Bosutinib—Immune system disorder—Doxorubicin—muscle cancer	0.000321	0.00173	CcSEcCtD
Bosutinib—Mediastinal disorder—Doxorubicin—muscle cancer	0.000321	0.00172	CcSEcCtD
Bosutinib—Leukopenia—Methotrexate—muscle cancer	0.00032	0.00172	CcSEcCtD
Bosutinib—PDGFRB—testis—muscle cancer	0.000312	0.000854	CbGeAlD
Bosutinib—Cough—Methotrexate—muscle cancer	0.000312	0.00168	CcSEcCtD
Bosutinib—ABL1—vagina—muscle cancer	0.000312	0.000853	CbGeAlD
Bosutinib—Vomiting—Etoposide—muscle cancer	0.00031	0.00167	CcSEcCtD
Bosutinib—Malnutrition—Doxorubicin—muscle cancer	0.00031	0.00166	CcSEcCtD
Bosutinib—Rash—Etoposide—muscle cancer	0.000307	0.00165	CcSEcCtD
Bosutinib—Dermatitis—Etoposide—muscle cancer	0.000307	0.00165	CcSEcCtD
Bosutinib—Headache—Etoposide—muscle cancer	0.000305	0.00164	CcSEcCtD
Bosutinib—Arthralgia—Methotrexate—muscle cancer	0.000304	0.00164	CcSEcCtD
Bosutinib—Myalgia—Methotrexate—muscle cancer	0.000304	0.00164	CcSEcCtD
Bosutinib—Chest pain—Methotrexate—muscle cancer	0.000304	0.00164	CcSEcCtD
Bosutinib—Dysgeusia—Doxorubicin—muscle cancer	0.000303	0.00163	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000302	0.00163	CcSEcCtD
Bosutinib—Discomfort—Methotrexate—muscle cancer	0.000301	0.00162	CcSEcCtD
Bosutinib—Back pain—Doxorubicin—muscle cancer	0.000299	0.00161	CcSEcCtD
Bosutinib—Anaphylactic shock—Methotrexate—muscle cancer	0.000292	0.00157	CcSEcCtD
Bosutinib—Infection—Methotrexate—muscle cancer	0.00029	0.00156	CcSEcCtD
Bosutinib—Nausea—Etoposide—muscle cancer	0.000289	0.00156	CcSEcCtD
Bosutinib—ABL1—head—muscle cancer	0.000288	0.000788	CbGeAlD
Bosutinib—Ill-defined disorder—Doxorubicin—muscle cancer	0.000287	0.00154	CcSEcCtD
Bosutinib—Nervous system disorder—Methotrexate—muscle cancer	0.000286	0.00154	CcSEcCtD
Bosutinib—Anaemia—Doxorubicin—muscle cancer	0.000286	0.00154	CcSEcCtD
Bosutinib—Thrombocytopenia—Methotrexate—muscle cancer	0.000286	0.00154	CcSEcCtD
Bosutinib—Skin disorder—Methotrexate—muscle cancer	0.000283	0.00152	CcSEcCtD
Bosutinib—Malaise—Doxorubicin—muscle cancer	0.000279	0.0015	CcSEcCtD
Bosutinib—ABL1—testis—muscle cancer	0.000278	0.000761	CbGeAlD
Bosutinib—Leukopenia—Doxorubicin—muscle cancer	0.000277	0.00149	CcSEcCtD
Bosutinib—CHEK2—Epirubicin—Doxorubicin—muscle cancer	0.000272	0.023	CbGdCrCtD
Bosutinib—Cough—Doxorubicin—muscle cancer	0.00027	0.00145	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000266	0.00143	CcSEcCtD
Bosutinib—Chest pain—Doxorubicin—muscle cancer	0.000264	0.00142	CcSEcCtD
Bosutinib—Myalgia—Doxorubicin—muscle cancer	0.000264	0.00142	CcSEcCtD
Bosutinib—Arthralgia—Doxorubicin—muscle cancer	0.000264	0.00142	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000262	0.00141	CcSEcCtD
Bosutinib—Discomfort—Doxorubicin—muscle cancer	0.00026	0.0014	CcSEcCtD
Bosutinib—Dyspnoea—Methotrexate—muscle cancer	0.00026	0.0014	CcSEcCtD
Bosutinib—ABL1—Idarubicin—Doxorubicin—muscle cancer	0.00026	0.0219	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Doxorubicin—muscle cancer	0.00026	0.0219	CbGdCrCtD
Bosutinib—ABL1—Epirubicin—Doxorubicin—muscle cancer	0.00026	0.0219	CbGdCrCtD
Bosutinib—Decreased appetite—Methotrexate—muscle cancer	0.000254	0.00136	CcSEcCtD
Bosutinib—Anaphylactic shock—Doxorubicin—muscle cancer	0.000253	0.00136	CcSEcCtD
Bosutinib—Oedema—Doxorubicin—muscle cancer	0.000253	0.00136	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000252	0.00135	CcSEcCtD
Bosutinib—Fatigue—Methotrexate—muscle cancer	0.000252	0.00135	CcSEcCtD
Bosutinib—Infection—Doxorubicin—muscle cancer	0.000251	0.00135	CcSEcCtD
Bosutinib—Pain—Methotrexate—muscle cancer	0.00025	0.00134	CcSEcCtD
Bosutinib—Nervous system disorder—Doxorubicin—muscle cancer	0.000248	0.00133	CcSEcCtD
Bosutinib—Thrombocytopenia—Doxorubicin—muscle cancer	0.000247	0.00133	CcSEcCtD
Bosutinib—Skin disorder—Doxorubicin—muscle cancer	0.000245	0.00132	CcSEcCtD
Bosutinib—Feeling abnormal—Methotrexate—muscle cancer	0.00024	0.00129	CcSEcCtD
Bosutinib—Gastrointestinal pain—Methotrexate—muscle cancer	0.000239	0.00128	CcSEcCtD
Bosutinib—Urticaria—Methotrexate—muscle cancer	0.000232	0.00125	CcSEcCtD
Bosutinib—Abdominal pain—Methotrexate—muscle cancer	0.000231	0.00124	CcSEcCtD
Bosutinib—Body temperature increased—Methotrexate—muscle cancer	0.000231	0.00124	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00023	0.00124	CcSEcCtD
Bosutinib—Dyspnoea—Doxorubicin—muscle cancer	0.000225	0.00121	CcSEcCtD
Bosutinib—Decreased appetite—Doxorubicin—muscle cancer	0.00022	0.00118	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000218	0.00117	CcSEcCtD
Bosutinib—Fatigue—Doxorubicin—muscle cancer	0.000218	0.00117	CcSEcCtD
Bosutinib—Pain—Doxorubicin—muscle cancer	0.000216	0.00116	CcSEcCtD
Bosutinib—Asthenia—Methotrexate—muscle cancer	0.000209	0.00113	CcSEcCtD
Bosutinib—Feeling abnormal—Doxorubicin—muscle cancer	0.000208	0.00112	CcSEcCtD
Bosutinib—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000207	0.00111	CcSEcCtD
Bosutinib—Pruritus—Methotrexate—muscle cancer	0.000206	0.00111	CcSEcCtD
Bosutinib—Urticaria—Doxorubicin—muscle cancer	0.000201	0.00108	CcSEcCtD
Bosutinib—Abdominal pain—Doxorubicin—muscle cancer	0.0002	0.00107	CcSEcCtD
Bosutinib—Body temperature increased—Doxorubicin—muscle cancer	0.0002	0.00107	CcSEcCtD
Bosutinib—Diarrhoea—Methotrexate—muscle cancer	0.0002	0.00107	CcSEcCtD
Bosutinib—Dizziness—Methotrexate—muscle cancer	0.000193	0.00104	CcSEcCtD
Bosutinib—CYP3A4—renal system—muscle cancer	0.000189	0.000517	CbGeAlD
Bosutinib—Vomiting—Methotrexate—muscle cancer	0.000186	0.000997	CcSEcCtD
Bosutinib—Rash—Methotrexate—muscle cancer	0.000184	0.000989	CcSEcCtD
Bosutinib—Dermatitis—Methotrexate—muscle cancer	0.000184	0.000988	CcSEcCtD
Bosutinib—Headache—Methotrexate—muscle cancer	0.000183	0.000983	CcSEcCtD
Bosutinib—Asthenia—Doxorubicin—muscle cancer	0.000181	0.000975	CcSEcCtD
Bosutinib—Pruritus—Doxorubicin—muscle cancer	0.000179	0.000961	CcSEcCtD
Bosutinib—ABCB1—embryo—muscle cancer	0.000177	0.000484	CbGeAlD
Bosutinib—Nausea—Methotrexate—muscle cancer	0.000173	0.000932	CcSEcCtD
Bosutinib—Diarrhoea—Doxorubicin—muscle cancer	0.000173	0.000929	CcSEcCtD
Bosutinib—Dizziness—Doxorubicin—muscle cancer	0.000167	0.000898	CcSEcCtD
Bosutinib—Vomiting—Doxorubicin—muscle cancer	0.000161	0.000864	CcSEcCtD
Bosutinib—Rash—Doxorubicin—muscle cancer	0.000159	0.000856	CcSEcCtD
Bosutinib—Dermatitis—Doxorubicin—muscle cancer	0.000159	0.000856	CcSEcCtD
Bosutinib—Headache—Doxorubicin—muscle cancer	0.000158	0.000851	CcSEcCtD
Bosutinib—Nausea—Doxorubicin—muscle cancer	0.00015	0.000807	CcSEcCtD
Bosutinib—ABCB1—renal system—muscle cancer	0.000134	0.000366	CbGeAlD
Bosutinib—ABCB1—bone marrow—muscle cancer	0.000101	0.000277	CbGeAlD
Bosutinib—ABCB1—vagina—muscle cancer	9.69e-05	0.000265	CbGeAlD
Bosutinib—ABCB1—head—muscle cancer	8.96e-05	0.000245	CbGeAlD
Bosutinib—ABCB1—testis—muscle cancer	8.65e-05	0.000237	CbGeAlD
Bosutinib—MAP2K1—Innate Immune System—MDM2—muscle cancer	2.04e-05	4.74e-05	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—VEGFA—muscle cancer	2.03e-05	4.71e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PTCH1—muscle cancer	2.03e-05	4.71e-05	CbGpPWpGaD
Bosutinib—BLK—Immune System—MDM2—muscle cancer	2.03e-05	4.7e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—FOXO1—muscle cancer	2.03e-05	4.7e-05	CbGpPWpGaD
Bosutinib—FGR—Immune System—MDM2—muscle cancer	2.02e-05	4.69e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PTCH1—muscle cancer	2.02e-05	4.69e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—FOXO1—muscle cancer	2.02e-05	4.68e-05	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—MDM2—muscle cancer	2e-05	4.65e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—KIT—muscle cancer	2e-05	4.64e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—FOXO1—muscle cancer	2e-05	4.64e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—FOXO1—muscle cancer	1.99e-05	4.63e-05	CbGpPWpGaD
Bosutinib—HCK—Disease—PTGS2—muscle cancer	1.99e-05	4.62e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—FOXO4—muscle cancer	1.99e-05	4.62e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—MDM2—muscle cancer	1.99e-05	4.61e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—FOXO1—muscle cancer	1.98e-05	4.6e-05	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—MDM2—muscle cancer	1.97e-05	4.58e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—KIT—muscle cancer	1.96e-05	4.56e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—FOXO1—muscle cancer	1.96e-05	4.54e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—MDM2—muscle cancer	1.95e-05	4.53e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—MDM2—muscle cancer	1.95e-05	4.53e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—MDM2—muscle cancer	1.95e-05	4.51e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IGF2—muscle cancer	1.94e-05	4.49e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—KIT—muscle cancer	1.92e-05	4.46e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—FOXO1—muscle cancer	1.91e-05	4.43e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IGF2—muscle cancer	1.91e-05	4.43e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—MDM2—muscle cancer	1.88e-05	4.37e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—VEGFA—muscle cancer	1.88e-05	4.36e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—PTGS2—muscle cancer	1.88e-05	4.35e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—MDM2—muscle cancer	1.86e-05	4.31e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—FOXO4—muscle cancer	1.86e-05	4.31e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—KIT—muscle cancer	1.85e-05	4.29e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—KIT—muscle cancer	1.85e-05	4.29e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—FOXO1—muscle cancer	1.84e-05	4.27e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—FOXO4—muscle cancer	1.84e-05	4.26e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—FOXO1—muscle cancer	1.83e-05	4.25e-05	CbGpPWpGaD
Bosutinib—SRC—Axon guidance—VEGFA—muscle cancer	1.83e-05	4.24e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CNR1—muscle cancer	1.82e-05	4.23e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—FOXO4—muscle cancer	1.81e-05	4.2e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IGF2—muscle cancer	1.81e-05	4.2e-05	CbGpPWpGaD
Bosutinib—PTK2—Hemostasis—TP53—muscle cancer	1.81e-05	4.2e-05	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—VEGFA—muscle cancer	1.79e-05	4.17e-05	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—VEGFA—muscle cancer	1.79e-05	4.15e-05	CbGpPWpGaD
Bosutinib—YES1—Hemostasis—TP53—muscle cancer	1.78e-05	4.14e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—FOXO1—muscle cancer	1.78e-05	4.13e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CNR1—muscle cancer	1.78e-05	4.13e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—MDM2—muscle cancer	1.78e-05	4.12e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—VEGFA—muscle cancer	1.78e-05	4.12e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—FOXO4—muscle cancer	1.77e-05	4.12e-05	CbGpPWpGaD
Bosutinib—FER—Signaling Pathways—TP53—muscle cancer	1.77e-05	4.11e-05	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—VEGFA—muscle cancer	1.77e-05	4.1e-05	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—VEGFA—muscle cancer	1.76e-05	4.09e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—VEGFA—muscle cancer	1.76e-05	4.08e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—FOXO1—muscle cancer	1.76e-05	4.08e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PTCH1—muscle cancer	1.75e-05	4.07e-05	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—VEGFA—muscle cancer	1.75e-05	4.07e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—FOXO4—muscle cancer	1.75e-05	4.05e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CNR1—muscle cancer	1.74e-05	4.04e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—FOXO4—muscle cancer	1.74e-05	4.03e-05	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—VEGFA—muscle cancer	1.73e-05	4.02e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—KIT—muscle cancer	1.73e-05	4.01e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—FOXO1—muscle cancer	1.72e-05	4e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—MDM2—muscle cancer	1.72e-05	3.98e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CNR1—muscle cancer	1.71e-05	3.98e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—MDM2—muscle cancer	1.71e-05	3.97e-05	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—MDM2—muscle cancer	1.71e-05	3.96e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CNR1—muscle cancer	1.7e-05	3.96e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IGF2—muscle cancer	1.7e-05	3.96e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—KIT—muscle cancer	1.7e-05	3.96e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PTCH1—muscle cancer	1.69e-05	3.92e-05	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—TP53—muscle cancer	1.68e-05	3.89e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—FOXO1—muscle cancer	1.67e-05	3.87e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—FOXO1—muscle cancer	1.66e-05	3.85e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—MDM2—muscle cancer	1.65e-05	3.84e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—PTGS2—muscle cancer	1.65e-05	3.84e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.65e-05	3.82e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—MDM2—muscle cancer	1.64e-05	3.81e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—KIT—muscle cancer	1.64e-05	3.81e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—MDM2—muscle cancer	1.63e-05	3.78e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—KIT—muscle cancer	1.62e-05	3.75e-05	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—TP53—muscle cancer	1.6e-05	3.71e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—FOXO1—muscle cancer	1.59e-05	3.69e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—KIT—muscle cancer	1.58e-05	3.67e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—KIT—muscle cancer	1.58e-05	3.67e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—KIT—muscle cancer	1.58e-05	3.66e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—MDM2—muscle cancer	1.58e-05	3.66e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—FOXO1—muscle cancer	1.57e-05	3.64e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—MDM2—muscle cancer	1.55e-05	3.59e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—KIT—muscle cancer	1.54e-05	3.58e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—KIT—muscle cancer	1.54e-05	3.57e-05	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—TP53—muscle cancer	1.53e-05	3.56e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—FOXO1—muscle cancer	1.53e-05	3.56e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—VEGFA—muscle cancer	1.53e-05	3.54e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—KIT—muscle cancer	1.53e-05	3.54e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—KIT—muscle cancer	1.52e-05	3.53e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—MDM2—muscle cancer	1.51e-05	3.51e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—KIT—muscle cancer	1.51e-05	3.51e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—VEGFA—muscle cancer	1.51e-05	3.5e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—FOXO4—muscle cancer	1.51e-05	3.5e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTCH1—muscle cancer	1.5e-05	3.47e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—KIT—muscle cancer	1.49e-05	3.46e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IGF2—muscle cancer	1.49e-05	3.46e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—VEGFA—muscle cancer	1.48e-05	3.44e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—VEGFA—muscle cancer	1.48e-05	3.44e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CNR1—muscle cancer	1.48e-05	3.44e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—FOXO1—muscle cancer	1.47e-05	3.41e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—MDM2—muscle cancer	1.46e-05	3.38e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—KIT—muscle cancer	1.46e-05	3.38e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—MDM2—muscle cancer	1.45e-05	3.38e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IGF2—muscle cancer	1.45e-05	3.37e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—FOXO4—muscle cancer	1.45e-05	3.37e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—VEGFA—muscle cancer	1.44e-05	3.35e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—VEGFA—muscle cancer	1.43e-05	3.32e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CNR1—muscle cancer	1.43e-05	3.31e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IGF2—muscle cancer	1.42e-05	3.3e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—KIT—muscle cancer	1.4e-05	3.26e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IGF2—muscle cancer	1.4e-05	3.25e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—KIT—muscle cancer	1.4e-05	3.24e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IGF2—muscle cancer	1.39e-05	3.23e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—FOXO1—muscle cancer	1.37e-05	3.18e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—MDM2—muscle cancer	1.36e-05	3.16e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—FOXO1—muscle cancer	1.36e-05	3.15e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—KIT—muscle cancer	1.36e-05	3.15e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—MDM2—muscle cancer	1.34e-05	3.12e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—TP53—muscle cancer	1.34e-05	3.11e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—KIT—muscle cancer	1.34e-05	3.11e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—FOXO1—muscle cancer	1.34e-05	3.1e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—FH—muscle cancer	1.34e-05	3.1e-05	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—TP53—muscle cancer	1.33e-05	3.09e-05	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—TP53—muscle cancer	1.32e-05	3.07e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—KIT—muscle cancer	1.31e-05	3.05e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—FOXO1—muscle cancer	1.31e-05	3.04e-05	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—TP53—muscle cancer	1.31e-05	3.04e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—VEGFA—muscle cancer	1.3e-05	3.02e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—MDM2—muscle cancer	1.29e-05	3e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—FOXO1—muscle cancer	1.29e-05	2.99e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FOXO4—muscle cancer	1.29e-05	2.99e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—FOXO1—muscle cancer	1.28e-05	2.98e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—VEGFA—muscle cancer	1.28e-05	2.96e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—MDM2—muscle cancer	1.27e-05	2.95e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—KIT—muscle cancer	1.27e-05	2.95e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—KIT—muscle cancer	1.27e-05	2.94e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CNR1—muscle cancer	1.26e-05	2.93e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—MDM2—muscle cancer	1.25e-05	2.89e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—MDM2—muscle cancer	1.25e-05	2.89e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.25e-05	2.89e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—MDM2—muscle cancer	1.24e-05	2.88e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—MED12—muscle cancer	1.23e-05	2.84e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—MDM2—muscle cancer	1.22e-05	2.82e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—KIT—muscle cancer	1.21e-05	2.81e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IGF2—muscle cancer	1.21e-05	2.81e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—MDM2—muscle cancer	1.21e-05	2.81e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—MDM2—muscle cancer	1.2e-05	2.79e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—MDM2—muscle cancer	1.2e-05	2.78e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—VEGFA—muscle cancer	1.2e-05	2.78e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KIT—muscle cancer	1.2e-05	2.77e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—MDM2—muscle cancer	1.19e-05	2.76e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—MDM2—muscle cancer	1.17e-05	2.73e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—KIT—muscle cancer	1.17e-05	2.71e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IGF2—muscle cancer	1.17e-05	2.71e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—MDM2—muscle cancer	1.15e-05	2.66e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—TP53—muscle cancer	1.14e-05	2.65e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—PTGS2—muscle cancer	1.13e-05	2.63e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—KIT—muscle cancer	1.12e-05	2.6e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—TP53—muscle cancer	1.12e-05	2.6e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—TP53—muscle cancer	1.12e-05	2.6e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ENO2—muscle cancer	1.12e-05	2.59e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—FOXO1—muscle cancer	1.11e-05	2.59e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—PTGS2—muscle cancer	1.11e-05	2.56e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—MDM2—muscle cancer	1.11e-05	2.56e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—MDM2—muscle cancer	1.1e-05	2.55e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—TP53—muscle cancer	1.09e-05	2.53e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—TP53—muscle cancer	1.08e-05	2.51e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—FOXO1—muscle cancer	1.07e-05	2.49e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MDM2—muscle cancer	1.07e-05	2.48e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—PTGS2—muscle cancer	1.07e-05	2.47e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PTGS2—muscle cancer	1.06e-05	2.46e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MDM2—muscle cancer	1.05e-05	2.45e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KIT—muscle cancer	1.04e-05	2.42e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—VEGFA—muscle cancer	1.03e-05	2.4e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—KIT—muscle cancer	1.03e-05	2.4e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—MDM2—muscle cancer	1.03e-05	2.4e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IGF2—muscle cancer	1.03e-05	2.4e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—VEGFA—muscle cancer	1.02e-05	2.37e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KIT—muscle cancer	1.02e-05	2.37e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MDM2—muscle cancer	1e-05	2.32e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KIT—muscle cancer	9.98e-06	2.32e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—MDM2—muscle cancer	9.97e-06	2.31e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KIT—muscle cancer	9.83e-06	2.28e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—VEGFA—muscle cancer	9.82e-06	2.28e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KIT—muscle cancer	9.77e-06	2.27e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—TP53—muscle cancer	9.65e-06	2.24e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—MDM2—muscle cancer	9.55e-06	2.22e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FOXO1—muscle cancer	9.51e-06	2.21e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—VEGFA—muscle cancer	9.46e-06	2.2e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—VEGFA—muscle cancer	9.46e-06	2.2e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MDM2—muscle cancer	9.42e-06	2.18e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—PTGS2—muscle cancer	9.2e-06	2.14e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—MDM2—muscle cancer	9.2e-06	2.14e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—VEGFA—muscle cancer	9.12e-06	2.12e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—TP53—muscle cancer	9.04e-06	2.1e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—PTGS2—muscle cancer	8.87e-06	2.06e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—MDM2—muscle cancer	8.82e-06	2.05e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KIT—muscle cancer	8.49e-06	1.97e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MDM2—muscle cancer	8.23e-06	1.91e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KIT—muscle cancer	8.18e-06	1.9e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—MDM2—muscle cancer	8.15e-06	1.89e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—VEGFA—muscle cancer	8.12e-06	1.88e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MDM2—muscle cancer	8.03e-06	1.86e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—VEGFA—muscle cancer	8.01e-06	1.86e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MDM2—muscle cancer	7.86e-06	1.82e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—PTGS2—muscle cancer	7.85e-06	1.82e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TP53—muscle cancer	7.82e-06	1.81e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MDM2—muscle cancer	7.74e-06	1.8e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—muscle cancer	7.7e-06	1.79e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MDM2—muscle cancer	7.7e-06	1.79e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—VEGFA—muscle cancer	7.59e-06	1.76e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MED12—muscle cancer	7.55e-06	1.75e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—muscle cancer	7.42e-06	1.72e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KIT—muscle cancer	7.24e-06	1.68e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—VEGFA—muscle cancer	7.15e-06	1.66e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—muscle cancer	7.15e-06	1.66e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—muscle cancer	7.15e-06	1.66e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—muscle cancer	6.89e-06	1.6e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ENO2—muscle cancer	6.88e-06	1.6e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MDM2—muscle cancer	6.69e-06	1.55e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MDM2—muscle cancer	6.44e-06	1.5e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—muscle cancer	6.25e-06	1.45e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—muscle cancer	6.13e-06	1.42e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—muscle cancer	6.1e-06	1.41e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—muscle cancer	6.05e-06	1.4e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—muscle cancer	5.97e-06	1.39e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—muscle cancer	5.88e-06	1.36e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—muscle cancer	5.85e-06	1.36e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—muscle cancer	5.74e-06	1.33e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MDM2—muscle cancer	5.7e-06	1.32e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—muscle cancer	5.4e-06	1.25e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—muscle cancer	5.08e-06	1.18e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—muscle cancer	4.89e-06	1.14e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—muscle cancer	4.72e-06	1.1e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—muscle cancer	4.61e-06	1.07e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—muscle cancer	4.51e-06	1.05e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—muscle cancer	4.44e-06	1.03e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—muscle cancer	4.42e-06	1.02e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—muscle cancer	4.33e-06	1.01e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—muscle cancer	3.89e-06	9.03e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—muscle cancer	3.84e-06	8.9e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—muscle cancer	3.7e-06	8.58e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—muscle cancer	3.27e-06	7.59e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—muscle cancer	2.4e-06	5.56e-06	CbGpPWpGaD
